MedTrace Logo

Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer

NCT04350021 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-01-17

No results posted yet for this study

Summary

Low dose metronomic chemotherapy (LDMC) in patients with metastatic breast cancer (MBC) is used as a palliative regiment with the aim to prolong and improve quality of life. The effect of LDMC is not fully elucidated. The aim is to evaluate the effect of LDMC with Capecitabine and Cyclophosphamide (CX) and to discover new potential predictive markers and potential markers for monitoring treatment effect.

Conditions

  • Breast Cancer Metastatic
  • Chemotherapy Effect

Interventions

DRUG

Capecitabine, Cyclophosphamide

Capecitabine 500 mg times three, Cyclophosphamide 50 mg once daily

Sponsors & Collaborators

  • Vastra Gotaland Region

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2023-10-30
Completion
2023-10-30
FDA Drug
Yes

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04350021 on ClinicalTrials.gov